Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet    (NTPH)


One Stock Crorepati: The Biggest Money-Making Opportunity Available Right Now

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 515.9
Mkt Cap Rs m 85,717
Vol '000 25.3
P/E X 17.7
P/CF X 11.8
EPS (TTM) Rs 29.2
% ch % 3.7
No. of shares m 166.15
% ch week % 3.8
% ch 1-mth % -16.5
% ch 12-mth % -8.1
52 week H/L Rs 737.8/450.0
(As on Apr 3, 2020 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs2,2916248491,080849 
Low Rs656366418671557 
Sales per share (Unadj.) Rs248.4327.8578.9592.1573.8 
Earnings per share (Unadj.) Rs37.643.5138.9188.4176.0 
Diluted earnings per shareRs7.59.129.241.838.7 
Cash flow per share (Unadj.) Rs51.858.2154.5206.3198.2 
Dividends per share (Unadj.) Rs5.001.256.758.256.25 
Adj. dividends per shareRs1.000.261.421.831.37 
Dividend yield (eoy) %0.30.31.10.90.9 
Book value per share (Unadj.) Rs254.6372.8473.8833.6842.7 
Adj. book value per shareRs50.978.199.5185.1185.1 
Shares outstanding (eoy) m33.2334.8334.9036.9036.50 
Bonus/Rights/Conversions  -ISISISBB 
Price / Sales ratio x5.91.51.11.51.2 
Avg P/E ratio x39.211.44.64.64.0 
P/CF ratio (eoy) x28.48.54.14.23.5 
Price / Book Value ratio x5.81.31.31.10.8 
Dividend payout %13.32.94.94.43.6 
Avg Mkt Cap Rs m48,96317,23022,11632,31125,660 
No. of employees `0003.11.34.44.85.0 
Total wages/salary Rs m1,3691,8672,4323,2563,559 
Avg. sales/employee Rs Th2,647.78,462.64,579.94,522.54,225.3 
Avg. wages/employee Rs Th439.31,383.8551.3674.0718.0 
Avg. net profit/employee Rs Th400.81,124.21,099.31,439.01,295.9 
NATCO PHARMA INCOME DATA
Net Sales Rs m8,25311,41620,20221,84820,945 
Other income Rs m1491081394041,302 
Total revenues Rs m8,40211,52420,34122,25222,247 
Gross profit Rs m2,1002,6406,8349,2847,948 
Depreciation Rs m473510544662810 
Interest Rs m317229185154193 
Profit before tax Rs m1,4592,0096,2448,8728,247 
Minority Interest Rs m-44-14000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-1510000 
Tax Rs m154791,3951,9201,823 
Profit after tax Rs m1,2491,5174,8496,9526,424 
Gross profit margin %25.423.133.842.537.9 
Effective tax rate %1.023.922.321.622.1 
Net profit margin %15.113.324.031.830.7 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m4,8308,32310,87321,30723,472 
Current liabilities Rs m4,1374,9296,2655,9207,287 
Net working cap to sales %8.429.722.870.477.3 
Current ratio x1.21.71.73.63.2 
Inventory Days Days97114637392 
Debtors Days Days85848610788 
Net fixed assets Rs m8,3899,25311,69314,98618,648 
Share capital Rs m332348349369365 
"Free" reserves Rs m7,94512,37316,14430,35334,525 
Net worth Rs m8,46112,98316,53430,76030,760 
Long term debt Rs m9700000 
Total assets Rs m13,84018,23823,17637,15143,031 
Interest coverage x5.69.834.858.643.7 
Debt to equity ratio x0.10000 
Sales to assets ratio x0.60.60.90.60.5 
Return on assets %11.39.621.719.115.4 
Return on equity %14.811.729.322.620.9 
Return on capital %16.817.138.929.327.4 
Exports to sales %34.727.5000 
Imports to sales %6.510.2000 
Exports (fob) Rs m2,8663,141000 
Imports (cif) Rs m5381,168000 
Fx inflow Rs m3,1563,4576,79310,32211,536 
Fx outflow Rs m9591,6882,2542,9782,939 
Net fx Rs m2,1971,7694,5387,3438,597 
NATCO PHARMA CASH FLOW
From Operations Rs m 927 1,024 3,458 4,636 6,688 
From Investments Rs m -1,148 -1,755 -2,994 -11,155 -6,122 
From Financial Activity Rs m 291 856 -477 6,509 -509 
Net Cashflow Rs m 22 117 -7 -18 66 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   STRIDES PHARMA SCIENCE  PIRAMAL ENTERPRISES  INDOCO REMEDIES  TTK HEALTHCARE  PANACEA BIOTECH  

Compare NATCO PHARMA With:   STRIDES PHARMA SCIENCE  PIRAMAL ENTERPRISES  INDOCO REMEDIES  TTK HEALTHCARE  PANACEA BIOTECH  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Views on news

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

One Stock that is All Charged Up for the Post Coronavirus Rebound (The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - CIPLA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS